Johnson & Johnson stock (US4781601046): oncology data and device recall in focus after ASCO update

Johnson & Johnson, one of the largest healthcare groups in the United States, remains in focus for New York Stock Exchange investors after presenting new oncology data at ASCO 2026 and managing a safety-related recall of Abiomed Impella heart pumps, while the stock continues to trade as a U.S. blue chip benchmark name.

On 05/29/2026, Johnson & Johnson reported updated Phase 1/1b CHRYSALIS-2 study results for its intravenous RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) in advanced non-small cell lung cancer patients with atypical EGFR mutations, highlighting that median overall survival, a secondary endpoint, reached nearly 3.5 years in this population, according to a company press release from Chicago ahead of ASCO 2026.Johnson & Johnson press release as of 05/29/2026

The company stated that the RYBREVANT plus LAZCLUZE combination produced consistent responses across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes, and that no new safety signals emerged with longer follow-up, with most adverse events reported as Grade 1 or 2 in the CHRYSALIS-2 study.Johnson & Johnson press release as of 05/29/2026

In parallel with the oncology update, Johnson & Johnson's Abiomed unit, based in the United States, has initiated a recall of specific Impella heart pump models after identifying a risk that could lead to serious patient harm, with the action classified as a Class I recall by U.S. authorities, according to a sector report dated 05/29/2026.MedTech Dive as of 05/29/2026

Abiomed has asked customers to quarantine and return affected Impella devices, and regulators in the United States have described this as the most serious type of recall, indicating that use of the devices could cause serious injuries or death; however, continued monitoring and corrective actions are underway as Johnson & Johnson works with clinical sites and authorities on risk mitigation.MedTech Dive as of 05/29/2026

The stock traded around the mid-USD 220 range on the NYSE in late May 2026 and has a market capitalization in excess of USD 500 billion, underlining Johnson & Johnson's role as a key U.S. healthcare constituent for institutional and retail investors alike, according to recent market data published on 05/30/2026.MarketBeat as of 05/30/2026

As of: 30.05.2026

By the editorial team - specialized in equity coverage.

Johnson & Johnson: core business model

Johnson & Johnson generates revenue across innovative pharmaceuticals, medical devices and consumer health brands, with growth closely linked to demand for specialty therapeutics, surgical and interventional technologies, and everyday healthcare products worldwide.

Recent corporate actions

In addition to the ongoing clinical development of RYBREVANT and LAZCLUZE in atypical EGFR-mutated non-small cell lung cancer, Johnson & Johnson has been reshaping its portfolio, including separating its consumer health unit Kenvue in 2023 and now preparing to spin off its orthopedics-focused DePuy Synthes business, a process that has included the planned elimination of 56 jobs at its New Brunswick headquarters, according to regional business media coverage in 2026.NJBIZ as of 2026

Insider activity and ownership structure

Recent regulatory filings and institutional reports indicate that Johnson & Johnson continues to be tightly held by a broad base of institutional investors in the United States, with shifts in individual positions illustrating active portfolio management rather than strategic control changes.

For example, an institutional investor such as WASHINGTON TRUST Co reported adjusting its position in Johnson & Johnson shares in a disclosure dated 05/30/2026, reflecting routine portfolio rebalancing in response to market conditions and valuation developments rather than signaling a strategic change in the company's ownership structure.MarketBeat as of 05/30/2026

Conclusion

Johnson & Johnson's latest ASCO 2026 data for RYBREVANT plus LAZCLUZE in atypical EGFR-mutated non-small cell lung cancer underlines the strategic importance of its oncology pipeline for long-term growth, while the Class I recall of Abiomed Impella heart pumps highlights the operational and reputational risks that can accompany complex medical technologies.

At the same time, incremental shifts in institutional shareholdings such as those reported by WASHINGTON TRUST Co demonstrate ongoing portfolio management in the background of a widely held U.S. blue chip healthcare stock, setting the stage for investors to weigh clinical progress, regulatory developments and balance sheet strength ahead of upcoming earnings communications.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.